Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name?

被引：0
|
作者：
Grant, S
Dent, P
机构：
[1] Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2004年 / 3卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：873 / 875
页数：3
相关论文
共 50 条
  • [41] Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
    Tan, AR
    Yang, XW
    Berman, A
    Zhai, SP
    Sparreboom, A
    Parr, AL
    Chow, C
    Brahim, JS
    Steinberg, SM
    Figg, WD
    Swain, SM
    CLINICAL CANCER RESEARCH, 2004, 10 (15) : 5038 - 5047
  • [42] Expression of the cyclin-dependent kinase inhibitor Dacapo is regulated by Cyclin E
    de Nooij, JC
    Graber, KH
    Hariharan, IK
    MECHANISMS OF DEVELOPMENT, 2000, 97 (1-2) : 73 - 83
  • [43] Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
    Bose, Prithviraj
    Simmons, Gary L.
    Grant, Steven
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 723 - 738
  • [44] Complexities in the development of cyclin-dependent kinase inhibitor drugs
    Sausville, EA
    TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) : S32 - S37
  • [45] Cyclin-Dependent Kinase Inhibitor-Associated Thromboembolism
    Olson, Sven R.
    DeLoughery, Thomas G.
    Shatzel, Joseph J.
    JAMA ONCOLOGY, 2019, 5 (02) : 141 - 142
  • [46] Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
    K A Blum
    A S Ruppert
    J A Woyach
    J A Jones
    L Andritsos
    J M Flynn
    B Rovin
    M Villalona-Calero
    J Ji
    M Phelps
    A J Johnson
    M R Grever
    J C Byrd
    Leukemia, 2011, 25 : 1444 - 1451
  • [47] Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)
    Lin, T. S.
    Andritsos, L. A.
    Jones, J. A.
    Fischer, B.
    Heerema, N. A.
    Blum, K. A.
    Flynn, J. M.
    Moran, M. E.
    Phelps, M. A.
    Grever, M. R.
    Byrd, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
    Blum, K. A.
    Ruppert, A. S.
    Woyach, J. A.
    Jones, J. A.
    Andritsos, L.
    Flynn, J. M.
    Rovin, B.
    Villalona-Calero, M.
    Ji, J.
    Phelps, M.
    Johnson, A. J.
    Grever, M. R.
    Byrd, J. C.
    LEUKEMIA, 2011, 25 (09) : 1444 - 1451
  • [49] Flavopiridol, an inhibitor of cyclin-dependent kinase 4, reverses cognitive deficits induced by β-amyloid peptide 1-42
    Impellizzeri, A.
    Leggio, G. M.
    Pellitteri, R.
    Spatuzza, M.
    Puzzo, D.
    Salomone, S.
    Navarria, A.
    Copani, A.
    Catania, M. V.
    Caraci, F.
    Drago, F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S628 - S628
  • [50] Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
    Mahoney, Emilia
    Byrd, John C.
    Johnson, Amy J.
    AUTOPHAGY, 2013, 9 (03) : 434 - 435
12345